Biotech Investors Cautious Amid Regulatory Changes

Biotech investors are expressing growing concern over the rare-disease sector due to recent regulatory changes. Wall Street Journal (Markets) posted on X that these changes, implemented under U.S. President Donald Trump's administration, have led to increased uncertainty in the market. The rare-disease space, once considered a promising area for investment due to its potential for high returns, is now facing scrutiny as investors reassess the risks associated with regulatory shifts. This apprehension is impacting investment strategies and could influence the future direction of biotech funding.